We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
After undershooting analyst sales forecasts in the first quarter, Eli Lilly’s psoriasis drug Taltz is on the hot seat in an immunology market packed with blockbusters.